VolitionRx Limited (VNRX) Stock Analysis — Probabli.AI
AI-powered analysis for VNRX (VolitionRx Limited): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $0.14 · Market cap: $22.2M · AI outlook: Bullish
VolitionRx Limited (VNRX) is a high-potential biotech firm focused on developing innovative non-invasive diagnostics for cancer. The firm's nucleosomics technology holds promise, supported by a strong positive sentiment among analysts, a high revenue growth trajectory, and new catalysts such as funding success and trial milestones. Risks remain due to its early-stage commercialization,…
Probabilistic 1-Year Outlook
- Bull 48% · Neutral 40% · Bear 12%
- 1-year price estimates — P10: $0 / P50: $0 / P90: $1
- VolitionRx Limited has demonstrated strong momentum through recent positive trial results and an impressive revenue growth estimate. The market sentiment, reflected in analysts' ratings and their estimates, also leans…
5-Year Outlook
- Bull 60% · Neutral 30% · Bear 10%
- 5-year price estimates — P10: $0 / P50: $5 / P90: $12
SWOT Highlights
- Strength: Innovative nucleosomics technology with promising trial results.
- Strength: High revenue growth potential as evidenced by current estimates.
- Risk: Currently low revenue base leading to operational uncertainty.
- Risk: Early-stage commercialized products with unproven scale.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
5 Wall Street analysts rate VNRX a BUY with a mean price target of $1.67.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
VNRX forecast details · VNRX sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.